rs751603831
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP3
The NM_001358530.2(MOCS1):c.1150G>A(p.Glu384Lys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000192 in 1,610,870 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001358530.2 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MOCS1 | NM_001358530.2 | c.1150G>A | p.Glu384Lys | missense_variant, splice_region_variant | 10/11 | ENST00000340692.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MOCS1 | ENST00000340692.10 | c.1150G>A | p.Glu384Lys | missense_variant, splice_region_variant | 10/11 | 5 | NM_001358530.2 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000134 AC: 2AN: 149486Hom.: 0 Cov.: 29
GnomAD4 exome AF: 0.0000198 AC: 29AN: 1461384Hom.: 0 Cov.: 31 AF XY: 0.0000261 AC XY: 19AN XY: 727014
GnomAD4 genome ? AF: 0.0000134 AC: 2AN: 149486Hom.: 0 Cov.: 29 AF XY: 0.00 AC XY: 0AN XY: 72722
ClinVar
Submissions by phenotype
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A Pathogenic:1Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 06, 2017 | The MOCS1 c.1150G>A (p.Gly384Ser) missense variant has been reported in one study and is found in a compound heterozygous state in one individual with molybdenum cofactor deficiency (Reiss et al. 1998). The p.Gly384Ser variant was absent from 50 control chromosomes and is reported at a frequency of 0.000067 in the European (non-Finnish) population of the Genome Aggregation Database, but this is based on one allele in a region of good sequence coverage so the variant is presumed to be rare. Expression analysis in E. coli found the p.Gly384Ser variant to have significantly reduced activity compared to wildtype (Hänzelmann et al. 2002). The p.Gly384 residue is conserved across mammals, plants, and bacteria (Reiss et al. 1998). Based on the evidence, the p.Gly384Ser variant is classified as a variant of unknown significance but suspicious for pathogenicity for molybdenum cofactor deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Invitae | Aug 10, 2022 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 384 of the MOCS1 protein (p.Gly384Ser). This variant is present in population databases (rs751603831, gnomAD 0.007%). This missense change has been observed in individual(s) with molybdenum cofactor deficiency (PMID: 9921896). ClinVar contains an entry for this variant (Variation ID: 534542). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects MOCS1 function (PMID: 11891227). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 25, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant in c.1150G>A(p.Glu384Lys) in MOCS1 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. The p.Glu384Lys variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes and has an allele frequency of 0.003203% from gnomAD database. This variant has been reported to the ClinVar database as Uncertain Significance (VUS). The amino acid change p.Glu384Lys in MOCS1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Glu at position 384 is changed to a Lys changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Variant of Uncertain Significance (VUS). The above variant has been observed in the spouse. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 26, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at